46brooklyn Research
Cart 0
News Research Visualizations Podcast
In the Media Glossary Our Team Donate
Cart 0
NewsResearchVisualizationsPodcast
46brooklyn Research
In the MediaGlossaryOur TeamDonate
 
46Brookly-2020-Website-Billboard-Designs46b-2.0-Billboard-3-Research.png
 
Same drug, thousands of prices: Crossing Medicare’s Catastrophic Coverage finish line
Same drug, thousands of prices: Crossing Medicare’s Catastrophic Coverage finish line
Ben LinkDecember 10, 2024Medicare, PBM, Part D, Copaxone, Inflation Reduction Act, Catastrophic Coverage, IRA, NADAC, Mark Cuban, MFP, Januvia, Novolog, Farxiga, Enbrel, Jardiance, Stelara, Xarelto, Eliquis, Entresto, Imbruvica, WAC, Express Scripts, CVS, Optum, Kaiser, 340B
Treating the drug pricing perception problem
Treating the drug pricing perception problem
Ben LinkSeptember 24, 2024Brand drugs, List prices, WAC, OhioHealth, Opdivo, chargemaster, Average Sales Price, ASP, CMS, WVU Hospitals
Medicare’s addiction to disconnected drug prices
Medicare’s addiction to disconnected drug prices
Ben LinkSeptember 10, 2024Generic, Medicare, PBM, Part D, AWP, dispensing fee, Transparency in Coverage, Suboxone, Buprenorphine-naloxone, opioid use disorder, addiction treatment, NADAC, Medicaid
How Mark Cuban reveals hidden costs of variable drug prices in Medicare
How Mark Cuban reveals hidden costs of variable drug prices in Medicare
Ben LinkJuly 22, 2024Generic, Medicare, PBM, Mark Cuban, Cost Plus Drugs, Part D, imatinib, Costco, CVS, Cigna, UnitedHealth
Money from Sick People Part IV: Paying a Premium for Drug Pricing Irregularity
Money from Sick People Part IV: Paying a Premium for Drug Pricing Irregularity
Ben LinkJuly 19, 2024List prices, WAC, Insulin, Lantus, PBM, Humalog, Rutledge v PCMA, diabetes, Inflation Reduction Act, Apidra, Novolog, Levemir, Medicare, Part D
Is 2024 the start of a brave new world in drug pricing?
Is 2024 the start of a brave new world in drug pricing?
Ben LinkJanuary 12, 2024WAC, AWP, PBM, Brand drugs, Generic drugs, NADAC, CVS, Express Scripts, Medicaid, Mark Cuban, Insulin, Flovent, Price increases, List prices, Rebates, American Rescue Plan, Inflation Reduction Act, AMP
How PBMs distort and undermine specialty drug pricing guarantees
How PBMs distort and undermine specialty drug pricing guarantees
Ben LinkMay 10, 2023Specialty, WAC, AWP, specialty drugs, PBM, Brand drugs, Generic drugs, Effective rate, NADAC, Linda Cahn, CVS, Express Scripts, Optum, Emgality, Retevmo, Imatinib, Gleevec, Hyalgan, Medicaid, Medicare, Mark Cuban, Ohio
Brand drug launch prices: A game of perspective
Brand drug launch prices: A game of perspective
Ben LinkMarch 9, 2023Rebates, Launch, drug prices, Brand drugs, Inflation Reduction Act, Medicare, Lyrica, WAC, Adbry, Firazyr, Zolgensma, Trikafta, CPI, List prices
Medicare hits $200 billion in gross drug spend: Who gets the blame?
Medicare hits $200 billion in gross drug spend: Who gets the blame?
Ben LinkApril 11, 2022Medicare, Part D, Brand drugs, Generic drugs, Specialty, DIR fees, Rebates, PBM, Eliquis, Revlimid, Xarelto, Januvia, Trulicity, Imbruvica, Lantus, Jardiance, Humira, Ibrance, NADAC, atorvastatin, WAC
Older
 

Subscribe

Sign up with your email address to receive our latest news and research.

We respect your privacy.

Thank you!
info@46brooklyn.com
Hours
ContactTerms of UsePrivacy Policy

© 2024 46brooklyn Research